Tim Kanters (PhD) is a senior scientific researcher at the institute for Medical Technology Assessment (iMTA), part of the Erasmus University Rotterdam. In this role, he is involved in cost-effectiveness studies, costing studies and real-world evidence studies in various clinical areas. He was involved in the two latest revisions of the Dutch costing manual for economic evaluations. His dissertation focussed on the cost-effectiveness of orphan drugs.